Mupirocin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Mupirocin: From Topical Antibacterial Use to Pleural Empyema
One-Sentence Summary
Mupirocin is a topical antibacterial that acts against Staphylococcus aureus. The TxGNN model predicts it may be effective for pleural empyema, but no clinical trials and no publications currently support this prediction. It rests on a computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Pleural empyema |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Mupirocin inhibits bacterial isoleucyl-tRNA synthetase and is active against Staphylococcus aureus. This organism can cause empyema, which is the only mechanistic bridge to the predicted indication. The evidence pack does not include a formal mechanism-of-action entry, so this description comes from the candidate’s rationale notes.
The bridge is weak. Mupirocin is a topical agent with no established systemic or intrapleural use. Empyema is a deep-seated pleural infection, so drug penetration, formulation and route would all be unresolved problems. The high TxGNN score reflects a computational association, not clinical support. No route compatibility assessment has been completed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 49/20.1.6/0587 | Supiroban Cream | Cream |
The only registered form is topical (cream). The record does not include approved indication text or Essential Medicines List status.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: Pleural empyema is supported only by a model score (L5), with no trials or literature. The topical-only formulation also does not fit a deep pleural infection.
To proceed, the following is needed:
- Obtain the SAHPRA package insert and extract its warnings and contraindications. This gap blocks safety screening.
- Complete the route compatibility assessment. A pleural indication would need a non-topical route or formulation, which is not registered in South Africa.
- Retrieve mechanism-of-action data from DrugBank.
- Search for direct clinical or preclinical evidence in pleural infection.
Note on other predictions for this drug: Staphylococcal scalded skin syndrome has more supporting evidence (L3, “Research Question”). This consists mainly of case reports, epidemiology studies and one 2023 study of IV antibiotics combined with 2% mupirocin ointment. It has no RCTs, and reports of mupirocin-resistant S. aureus clones are a stewardship concern. It may be a better candidate for follow-up than pleural empyema.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.